The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors

The β(3)‐adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity‐related metabolic diseases in humans, including those involving disturbances of glucose homeostasis. We investigated the effect of mirabegron on glucose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacol Res Perspect
Hauptverfasser: Dehvari, Nodi, Sato, Masaaki, Bokhari, Muhammad Hamza, Kalinovich, Anastasia, Ham, Seungmin, Gao, Jie, Nguyen, Huong T. M., Whiting, Lynda, Mukaida, Saori, Merlin, Jon, Chia, Ling Yeong, Wootten, Denise, Summers, Roger J., Evans, Bronwyn A., Bengtsson, Tore, Hutchinson, Dana S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437350/
https://ncbi.nlm.nih.gov/pubmed/32813332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.643
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge